New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
08:59 EDTINFIInfinity Pharmaceuticals 827K share Block Trade priced at $35.70
The deal range was $35.60-$35.75. UBS acted as sole book running manager for the offering.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
13:01 EDTINFINomura sees more M&A following AbbVie's acquisition of Pharmacyclics
Nomura believes AbbVie's (ABBV) acquisition of Pharmacyclics (PCYC) supports its call that Receptos (RCPT) and Infinity Pharmaceuticals (ICPT) are on the top of M&A lists given both companies have potential $5B in peaks sales potential and unencumbered assets. Additionally, the firm believes the deal has positive implications for Neutral rated Incyte (INFI) given the potential AbbVie can now evaluate ABT-199 in combination with Incyte's duvelisib and Pharmacyclic's Imbruviea across a range of hematological malignancies.
February 24, 2015
16:04 EDTINFIInfinity Pharmaceuticals reports Q4 EPS (83c), consensus (98c)
Reports Q4 revenue $4.36M, consensus $5.61M. Completion of patient enrollment in DYNAMO and DUO trials expected in 2015, topline data from DYNAMO is anticipated in the second half of 2015 and three new clinical studies of Duvelisib are expected to begin in 2015, the company said. At December 31, 2014, Infinity had total cash, cash equivalents and available-for-sale securities of $333.2M, compared to $214.5M at December 31, 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use